Non‑invasive CGM announced

Know Labs published the KnowU product release on February 27, 2024 and the company trades on the NYSE American under the ticker KNW. (businesswire.com) The device uses Know Labs’ Bio‑RF/ dielectric spectroscopy approach, broadcasting a range of radio frequencies and recording voltage responses across those frequencies, then converting those signals to glucose estimates with on‑device machine‑learning models. (businesswire.com) KnowU’s announced form factors include an adhesive clip and a wrist/forearm strap, and the company says the wearable contains onboard computing, a rechargeable battery, no consumable test strips, and a companion mobile app. (knowlabs.co) Know Labs has stated the sensor integrated in KnowU is the component it intends to submit to the U.S. Food and Drug Administration and said it planned large‑scale external clinical trials during 2024 to refine continuous‑wear performance and algorithms. (businesswire.com) In interim accuracy updates, Know Labs reported narrowing its error gap and that a study measuring its sensor against a Dexcom G6 reference produced a mean absolute relative difference (MARD) near 11.3% in the company’s analyses. (fiercebiotech.com) Know Labs’ investor materials say the company holds a broad IP portfolio—citing more than 270 patents issued, pending, and in process—and the firm projects a low bill of materials that could make KnowU several‑times less expensive than current options (the company uses a 3x–5x figure). (knowlabs.co) The company identified Ron Erickson as chairman and CEO in its release and lists James H. “Andy” Anderson, MD, a former Eli Lilly diabetes leader, as its chief medical officer overseeing clinical development. (businesswire.com)